Benefit of adjuvant systemic therapies in HR+ HER2- pT1ab node-negative breast carcinomas

MLA

Roman Rouzier, et al. “Benefit of Adjuvant Systemic Therapies in HR+ HER2- PT1ab Node-Negative Breast Carcinomas.” Annals of Oncology, vol. 29, Oct. 2018, p. viii63. EBSCOhost, https://doi.org/10.1093/annonc/mdy270.193.

APA

Roman Rouzier, Emile Daraï, Fabien Reyal, Charles Coutant, P. Crochet, J-M Classe, A.-S. Azuar, Pierre-Emmanuel Colombo, Monique Cohen, Guillaume Blache, Chafika Mazouni, M.-P. Chauvet, G. Houvenaeghel, Richard Villet, Jean-Marie Boher, A. De Nonneville, Eric Lambaudie, A. Gonçalves, Eva Jouve, & P. Gimbergues. (2018). Benefit of adjuvant systemic therapies in HR+ HER2- pT1ab node-negative breast carcinomas. Annals of Oncology, 29, viii63. https://doi.org/10.1093/annonc/mdy270.193

Chicago

Roman Rouzier, Emile Daraï, Fabien Reyal, Charles Coutant, P. Crochet, J-M Classe, A.-S. Azuar, et al. 2018. “Benefit of Adjuvant Systemic Therapies in HR+ HER2- PT1ab Node-Negative Breast Carcinomas.” Annals of Oncology 29 (October): viii63. doi:10.1093/annonc/mdy270.193.